Business, energy, technology, markets and global industry news from Business News Today

ovarian cancer

PharmaDeviceNews ovarian cancer
Representative image: Cancer immunotherapy research advances as Anixa Biosciences evaluates its breast cancer vaccine and lira-cel CAR-T therapy in early-stage clinical trials.
Pharma & Biotech

Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?

Anixa Biosciences has presented completed Phase 1 data for its alpha-lactalbumin breast cancer vaccine and updated survival observations for liraltagene autoleucel in recurrent ovarian cancer. The findings strengthen the biological rationale behind both programmes, but controlled efficacy evidence, biomarker clarity and successful dose optimisation remain essential before either platform can be considered clinically validated.

Read More
Representative image: Antengene’s ATG-106 licensing deal highlights growing biotech interest in CDH6 x CD3 T cell engagers for solid tumor immunotherapy.
Pharma & Biotech

Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs

Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.

Read More
An oncologist reviews pelvic imaging with a patient as TORL BioTherapeutics evaluates ixotatug vedotin as a Claudin 6-targeted treatment for recurrent and platinum-resistant ovarian cancer. Representative image.
Pharma & Biotech

Can TORL’s ixotatug vedotin carve out a new targeted role in recurrent ovarian cancer?

Early ixotatug vedotin and bevacizumab data suggest activity in Claudin 6-positive ovarian cancer, but the small uncontrolled study cannot yet separate ADC efficacy from combination effects.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Representative image: A clinical genomics researcher reviews whole-genome sequencing data, reflecting Inocras’ ASCO 2026 findings on WGS-HRD testing and PARP inhibitor benefit in high-grade serous ovarian cancer.
Medical Devices & Diagnostics

Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?

PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.

Read More
Pharma & Biotech

Why OnCusp Therapeutics’ CFO hire matters for its CDH6 antibody-drug conjugate strategy

CDH6 ADCs are heating up. OnCusp Therapeutics now needs capital discipline to turn CUSP06 promise into clinical and investor credibility.

Read More
Pharma & Biotech

What Epitopea’s MHRA-approved OVACT trial signals for off-the-shelf cancer vaccines

Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.

Read More
Pharma & Biotech

Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?

Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.

Read More
Pharma & Biotech

Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough?

Debiopharm’s ovarian cancer combo won FDA Fast Track after AACR 2026 data. Read what it means for DDR therapy, biomarkers, and clinical risk.

Read More
Representative image of blood-based ctDNA testing and molecular residual disease monitoring, reflecting the AACR 2026 focus on SAGA Diagnostics’ Pathlight platform in metastatic breast cancer and ovarian cancer.
Medical Devices & Diagnostics

AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer

Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.

Read More